Intra-Cellular Therapies Shares Outstanding 2013-2024 | ITCI

Intra-Cellular Therapies shares outstanding for the quarter ending September 30, 2024 were 0.106B, a 10.01% increase year-over-year.

  • Intra-Cellular Therapies 2023 shares outstanding were 0.096B, a 1.95% increase from 2022.
  • Intra-Cellular Therapies 2022 shares outstanding were 0.094B, a 15.75% increase from 2021.
  • Intra-Cellular Therapies 2021 shares outstanding were 0.081B, a 15.47% increase from 2020.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Intra-Cellular Therapies Shares Outstanding 2013-2024 | ITCI

  • Intra-Cellular Therapies 2023 shares outstanding were 0.096B, a 1.95% increase from 2022.
  • Intra-Cellular Therapies 2022 shares outstanding were 0.094B, a 15.75% increase from 2021.
  • Intra-Cellular Therapies 2021 shares outstanding were 0.081B, a 15.47% increase from 2020.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$150.5B
Bristol Myers Squibb (BMY)$118.1B
Vertex Pharmaceuticals (VRTX)$115.4B
Gilead Sciences (GILD)$109.4B
CSL (CSLLY)$85.4B
Regeneron Pharmaceuticals (REGN)$81.8B
GSK (GSK)$69.3B
Argenex SE (ARGX)$34.4B
Alnylam Pharmaceuticals (ALNY)$30.2B
BioNTech SE (BNTX)$25.5B
Biogen (BIIB)$22.6B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$18.3B
Moderna (MRNA)$14.3B
Incyte (INCY)$13.6B
Genmab (GMAB)$13.6B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.8B
Vaxcyte (PCVX)$10.9B
Bio-Techne Corp (TECH)$10.5B
Sarepta Therapeutics (SRPT)$10.2B
Exact Sciences (EXAS)$10B
Exelixis (EXEL)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
QIAGEN (QGEN)$9.3B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$7.5B
Repligen (RGEN)$7.2B
Legend Biotech (LEGN)$7B